| Basics |
Penumbra, Inc.
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures.
|
| IPO Date: |
September 18, 2015 |
| Sector: |
Healthcare |
| Industry: |
Medical Devices |
| Market Cap: |
$9.71B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$3.05 | 1.78%
|
| Avg Daily Range (30 D): |
$2.75 | 1.07%
|
| Avg Daily Range (90 D): |
$2.72 | 1.07%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.29M |
| Avg Daily Volume (30 D): |
.25M |
| Avg Daily Volume (90 D): |
.31M |
| Trade Size |
| Avg Trade Size (Sh.): |
50 |
| Avg Trade Size (Sh.) (30 D): |
28 |
| Avg Trade Size (Sh.) (90 D): |
31 |
| Institutional Trades |
| Total Inst.Trades: |
3,748 |
| Avg Inst. Trade: |
$5.94M |
| Avg Inst. Trade (30 D): |
$13.81M |
| Avg Inst. Trade (90 D): |
$13.55M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$7.61M |
| Avg Closing Trade (30 D): |
$15.65M |
| Avg Closing Trade (90 D): |
$18.07M |
| Avg Closing Volume: |
38.02K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$3.82
|
$1.17
|
$1.02
|
|
Diluted EPS
|
$3.77
|
$1.15
|
$1
|
|
Revenue
|
$ 1.28B
|
$ 339.46M
|
$ 324.14M
|
|
Gross Profit
|
$ 850.92M
|
$ 224.01M
|
$ 215.88M
|
|
Net Income / Loss
|
$ 147.7M
|
$ 45.27M
|
$ 39.22M
|
|
Operating Income / Loss
|
$ 159.32M
|
$ 40.83M
|
$ 40.35M
|
|
Cost of Revenue
|
$ 429.23M
|
$ 115.45M
|
$ 108.26M
|
|
Net Cash Flow
|
$ 133.44M
|
$ 45.71M
|
$ 51.65M
|
|
PE Ratio
|
67.53
|
|
|
|
|
|
